Featured News

We are well on the way to assembling a grassroots advocacy team that can help make celiac disease a national priority in communities across the country

Researchers at the Mucosal Immunology and Biology Research Center (MIBRC) at Massachusetts General Hospital, led by Stefania Seger and CDF Medical Advisory Board member Alessio Fasano, have created 3-D, miniature models of the intestines in order to research celiac disease.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

As I return to Los Angeles, I would like to take a moment to share with you some of the highlights of our productive two days in Washington, DC. Your consistent support has allowed us to reach this tipping point, and I want to be clear about what your gifts of time, money, and advocacy…

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…